Navigation Links
Cadus Reports First Quarter 2008 Results

NEW YORK, May 15 /PRNewswire-FirstCall/ -- Cadus Corporation (OTC Bulletin Board: KDUS) announced today financial results for the first quarter ended March 31, 2008.

Revenues for the first quarter of 2008 were $100,000, compared to $100,000 for the same period in 2007. Net loss for the first quarter of 2008 was $207,996, compared to net loss of $558,469 for the same period in 2007. The decrease in net loss can be attributed to a decrease in general and administrative expenses of $47,207 and the 2007 loss on write down of marketable securities of $668,246, offset by a $279,906 reduction in short term investment to net asset value in 2008, and decreases in interest income and income from equity in other ventures of $84,129 and $945, respectively. Basic net loss per share for the first quarter of 2008 was $0.02, compared to basic net loss per share for the first quarter of 2007 of $0.04. Revenues for the first quarter of 2008 and 2007 consisted solely of a licensing fee paid by OSI Pharmaceuticals, Inc. for its non-exclusive license to Cadus's yeast technologies.

As of March 31, 2008, Cadus had 13,144,040 shares outstanding.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2007. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of patent protection and the risk of obsolescence of the company's technologies.


Condensed Consolidated Balance Sheets


March 31, December 31,

2008 2007

(Unaudited) (Audited)

Current assets:

Cash and cash equivalents $10,280,130 $2,444,376

Short term investments 14,953,960 22,960,545

Interest receivable 46,186 102,518

Prepaid and other current assets 126,150 1,150

Total current assets 25,406,426 25,508,589

Investment in other ventures 189,066 186,790

Patents, net 529,226 550,834

Total assets $26,124,718 $26,246,213


Current liabilities:

Accrued expenses and other

current liabilities $108,853 $22,352

Total current liabilities 108,853 22,352


Stockholders' equity:

Common stock 132,857 132,857

Additional paid-in capital 59,847,149 59,847,149

Accumulated deficit (33,664,066) (33,456,070)

Treasury stock (300,075) (300,075)

Total stockholders' equity 26,015,865 26,223,861

Total liabilities and

stockholder's equity $26,124,718 $26,246,213


Condensed Consolidated Statements of Operations

Three Months Ended

March 31,

2008 2007

(Unaudited) (Unaudited)

License and maintenance fees $100,000 $100,000

Total revenues 100,000 100,000

Costs and expenses:

General and administrative expenses 245,276 292,483

Amortization of patent costs 21,608 21,608

(Income) from equity in other ventures (2,276) (3,221)

Total costs and expenses 264,608 310,870

Operating loss (164,608) (210,870)

Other income:

Interest income 236,518 320,647

Loss on write down of marketable securities -- (668,246)

Investment reduction to net asset value (279,906) --

Loss before provision for income taxes (207,996) (558,469)

Provision for income taxes -- --

Net loss ($207,996) ($558,469)

Basic and diluted (loss) per weighted

average share of common stock outstanding ($0.02) ($0.04)

Weighted average shares of common stock

outstanding - basic and diluted 13,144,040 13,144,040

SOURCE Cadus Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadus Reports Second Quarter 2007 Results
2. Cadus Reports Third Quarter 2007 Results
3. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
4. SPO Medical Reports First Quarter 2008 Results
5. Nile Therapeutics Reports 2008 First Quarter Financial Results
6. Derma Sciences Reports First Quarter 2008 Results
7. NeurogesX Reports First Quarter 2008 Results
8. Spherix Reports 1st Quarter Earnings
9. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
10. PharmAthene Reports First Quarter 2008 Financial Results
11. Insulet Reports First Quarter 2008 Results
Post Your Comments:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation President ... and Astronomy, has been selected for membership in ARCS Alumni Hall of Fame ... Prize in Fundamental physics for the discovery of the accelerating expansion of the universe, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography (sEMG) ... tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase III ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):